ENDRA Life Sciences Inc.
NDRA
$3.98
$0.529915.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -11.51M | -8.82M | -9.57M | -9.89M | -10.06M |
| Total Depreciation and Amortization | 206.20K | 221.00K | 237.40K | 260.00K | 275.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.77M | 1.80M | 1.18M | 1.39M | 1.16M |
| Change in Net Operating Assets | 134.10K | -1.27M | -857.00K | -944.20K | -923.30K |
| Cash from Operations | -7.40M | -8.06M | -9.00M | -9.19M | -9.55M |
| Capital Expenditure | -16.00K | -22.90K | -22.90K | -33.90K | -33.90K |
| Sale of Property, Plant, and Equipment | 3.20K | 12.40K | 12.40K | 12.40K | 9.20K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -12.80K | -10.50K | -10.50K | -21.50K | -24.70K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -28.50K | -28.50K | -28.50K | -28.50K | -- |
| Issuance of Common Stock | 7.84M | 8.49M | 9.61M | 6.98M | 6.48M |
| Repurchase of Common Stock | -6.69M | -6.69M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 6.69M | 7.70M | 1.01M | 1.04M | 1.04M |
| Cash from Financing | 7.81M | 9.48M | 10.59M | 7.99M | 7.52M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | -- | -- | -- |
| Net Change in Cash | 395.60K | 1.41M | 1.58M | -1.22M | -2.06M |